Seer(SEER) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Fourth quarter revenue was $4.2 million, bringing full year 2025 revenue to $16.6 million, representing 17% year-over-year growth [4][27] - Total revenue for the fourth quarter of 2025 increased by 5% compared to $4 million in the fourth quarter of 2024, primarily due to higher product revenue [24] - Net loss for the fourth quarter of 2025 was $16 million, compared to $21.7 million in the fourth quarter of 2024 [26] Business Line Data and Key Metrics Changes - Product revenue for the fourth quarter of 2025 was $2.8 million, consisting of sales of Proteograph instruments and consumable kits [24] - Service revenue for the fourth quarter of 2025 was $1.2 million, primarily from STAC service projects [24] - Consumable kit volume increased by approximately 69% year-over-year, reflecting increasing utilization of technology [28] Market Data and Key Metrics Changes - The installed base of instruments grew by 67% to 82 instruments by the end of 2025 [30] - Approximately 60% of the instruments installed in 2025 were part of the Strategic Instrument Placement program [21] - The company recognized $761,000 of related party revenue in 2025, compared to $2.3 million in 2024, indicating a transition in customer focus [27] Company Strategy and Development Direction - Innovation is a key strategic differentiator, with a focus on building a world-class life science tools company [8] - The company plans to commercialize a proteoform profiling assay kit in 2027, expanding its addressable market [13] - The board has authorized an additional $25 million share repurchase program, reflecting confidence in long-term intrinsic value [33] Management's Comments on Operating Environment and Future Outlook - Management noted ongoing budgetary pressures and uncertainty around NIH funding impacting customer spending decisions [4] - The guidance for 2026 expects revenue in the range of $16 million to $18 million, reflecting cautious customer behavior due to funding uncertainties [35][36] - Management expressed optimism about the potential for significant revenue growth once the value of the new platform becomes clear [47] Other Important Information - The company ended the year with approximately $241 million in cash equivalents and investments, sufficient to reach cash flow breakeven [34] - A tax benefit preservation plan was adopted to protect net operating loss carry-forwards, with an NOL balance of approximately $262 million [35] Q&A Session Summary Question: Can you walk us through some of the challenges in the fourth quarter? - Management indicated that delays in NIH funding caused some customers to postpone purchases from the fourth quarter into 2026 [42] Question: What factors are limiting growth in 2026 despite momentum in 2025? - Management acknowledged that while there is momentum, the cautious spending environment and the need for clear momentum in customer engagement are challenges [44][45] Question: Are there any other factors limiting adoption beyond funding? - Management noted that the growing body of publications and customer feedback reflects the profound biological insights enabled by untargeted proteomics [50]